No genetic correlation was seen with Merck & Co's CETP inhibitor, but Dalcor believes that things will be different for dalcetrapib.
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.